Introduction
============

During the past 15 years, the number of clinically available antifungal agents has increased substantially. Many of these newer agents have a broader spectrum of activity than fluconazole and reduced toxicities compared to amphotericin B deoxycholate. One reason for the increased number of available antifungal agents is the recognition that invasive fungal infections remain a significant clinical problem. In the United States, *Candida* species are the fourth most common cause of nosocomial bloodstream infections ([@b116-idr-1-063]), and are associated with significant morbidity and mortality, with studies reporting crude mortality rates of approximately 40% ([@b116-idr-1-063]; [@b91-idr-1-063]). Reports have also demonstrated increased frequency of non-*Candida albicans* species, which may have clinical consequences as some species such as *C. krusei* and *C. glabrata* have reduced susceptibility to fluconazole and other azoles ([@b9-idr-1-063]; [@b68-idr-1-063]; [@b91-idr-1-063]). In addition to invasive candidiasis, the incidence of infections caused by *Aspergillus* species has increased over the last decade at major cancer centers and it is a major cause of infectious disease-related morbidity and mortality in immunocompromised patients, including those with hematologic malignancies, solid organ transplant recipients, and those undergoing hematopoietic stem cell transplantation ([@b6-idr-1-063]; [@b64-idr-1-063]; [@b70-idr-1-063]; [@b32-idr-1-063]; [@b69-idr-1-063]).

The development and introduction of new azoles and lipid formulations of amphotericin B have not fully overcome the toxicity and drug interaction limitations associated with these antifungal classes ([@b113-idr-1-063]). Recently, the echinocandins, including micafungin, caspofungin, and anidulafungin, have become available for clinical use. Echinocandins inhibit (1→3)-β-D-glucan synthase, limiting the production of (1→3)-β-D-glucan, an essential component of the fungal cell wall ([@b26-idr-1-063]). This is an attractive target for antifungal activity as human cells lack a homologous enzyme, thereby avoiding significant collateral toxicities and drug interactions associated with the azoles and amphotericin B. In the United States, micafungin is currently approved for the treatment of esophageal candidiasis, candidemia, acute disseminated candidiasis, *Candida* peritonitis and abscesses, and as prophylaxis against *Candida* infections in patients undergoing hematopoietic stell cell transplantation ([@b76-idr-1-063]). The purpose of this review is to discuss the pharmacology, clinical microbiology, mechanisms of resistance, safety, and clinical efficacy of micafungin in the treatment of invasive candidiasis and invasive aspergillosis.

Pharmacology
============

Mechanism of action
-------------------

(1→3)-β-D-glucans are polysaccharides that are synthesized by the glucan synthase complex bound to the fungal cell membrane. These polysaccharides are a major component of the fungal cell wall contributing to its shape and integrity. Through non-competitive inhibition of the glucan synthase enzyme complex, the echinocandins lead to depletion of (1→3)-β-D-glucan within the cell wall, resulting in osmostic instability and cell wall lysis ([@b57-idr-1-063]; [@b26-idr-1-063]; [@b10-idr-1-063]). Against *Candida* species, exposure to micafungin may result in fungicidal activity ([@b28-idr-1-063]). In this setting the minimum inhibitory concentration (MIC), which measures reductions in visible growth, may be used to assess in vitro drug activity. The echinocandins display unique patterns of growth inhibition against filamentous fungi, including *Aspergillus* and *Scedosporium* species, due to the glucan synthase complex being located at the growing apical tips ([@b8-idr-1-063]). In these organisms, exposure to an echinocandin results in aberrant hyphal growth with an abundance of short, stubby branches ([@b111-idr-1-063]; [@b10-idr-1-063]). Thus, the minimum effective concentration (MEC) has been used as an alternative to the MIC for measuring in vitro echinocandin activity against filamentous fungi. In vitro studies have demonstrated that the MEC, defined as the lowest concentration of an echinocandin resulting in abnormally branched stubby hyphae, is a consistent measure of in vitro echinocandin activity ([@b4-idr-1-063]; [@b5-idr-1-063]).

Clinical microbiology
---------------------

Micafungin is a relatively broad-spectrum antifungal agent with in vitro activity against *Candida* and *Aspergillus* species, as well as the mycelial forms of dimorphic fungi. The most potent activity of micafungin is against *Candida*, including non-*Candida albicans* species ([Table 1](#t1-idr-1-063){ref-type="table"}), and is conserved against clinically invasive isolates resistant to fluconazole ([@b29-idr-1-063]; [@b81-idr-1-063]; [@b73-idr-1-063]; [@b90-idr-1-063]; [@b91-idr-1-063]). Micafungin and the other available echinocandins lack in vitro activity against *Cryptococcus neoformans*, *Fusarium* species, *Trichosporon* species, and the Zygomycetes ([@b33-idr-1-063]; [@b29-idr-1-063]; [@b42-idr-1-063]; [@b72-idr-1-063]). Against most *Candida* species, the MIC~90~ ranges from 0.015 to 0.5 μg/mL ([Table 1](#t1-idr-1-063){ref-type="table"}). However, similar to anidulafungin and caspofungin, the potency of micafungin is reduced against *C. parapsilosis*, *C. orthopsilosis*, *C. metapsilosis*, *C. guilliermondii*, and *C. lusitaniae*, with MIC~90~ values ranging from 0.25 to 8 μg/mL ([@b102-idr-1-063]; [@b81-idr-1-063]; [@b90-idr-1-063]; [@b30-idr-1-063]). Although some patients with infections caused by these species have been reported to respond to echinocandin therapy, the clinical significance of this reduced potency is unclear as clinical trials have not been powered to assess efficacy against these species ([@b75-idr-1-063]; [@b58-idr-1-063]; [@b84-idr-1-063]; [@b95-idr-1-063]).

Micafungin also exhibits significant in vitro activity against *Aspergillus* species, with MEC values reported to be ≤0.125 μg/mL ([Table 1](#t1-idr-1-063){ref-type="table"}) ([@b5-idr-1-063]). In contrast, higher values have been reported against *Aspergillus* species when the MIC endpoint has been used ([@b5-idr-1-063]; [@b42-idr-1-063]). This may reflect the limitation of using the MIC endpoint as a measure of echinocandin in vitro activity against filamentous fungi. Similarly, MEC values of the echinocandins against *Scedosporium* are lower than the corresponding MIC values ([@b4-idr-1-063]; [@b5-idr-1-063]). The activity of this class against *Scedosporium* species is markedly reduced compared to that reported against *Aspergillus*. In addition to *Candida* and *Aspergillus* species, micafungin also has potent in vitro activity against the mycelial forms of dimorphic fungi, such as *Histoplasma capsulatum* and *Blastomyces dermatitidis*, but limited activity against the yeast morphology of these pathogens encountered clinically ([@b78-idr-1-063]). This difference in potency has been attributed to the limited amount of (1→3)-β-D-glucan within the cell walls of the yeast forms ([@b25-idr-1-063]; [@b48-idr-1-063]; [@b49-idr-1-063]; [@b78-idr-1-063]). This activity against the mycelial forms of dimorphic fungi has limited clinical relevance, as it is the yeast morphology that is associated with clinical disease. Indeed, data from animal models have demonstrated poor activity of the echinocandins against infections caused by dimorphic fungi ([@b34-idr-1-063]; [@b51-idr-1-063]).

Recently, the Clinical and Laboratory Standards Institute (CLSI) Antifungal Subcommittee has developed recommendations for echinocandin susceptibility testing, including breakpoints for classifying *Candida* isolates as susceptible to members of this antifungal class ([@b89-idr-1-063]). Briefly, the CLSI-endorsed broth microdilution method for echinocandins is similar to that for azoles. One difference is that for the echinocandins the visual endpoint is read after 24 hours of incubation as opposed to 48 hours for the azoles. Good correlation between clinical outcomes and the echinocandin breakpoint for susceptible isolates (MIC of ≤2 μg/mL) has been observed using these methods ([@b92-idr-1-063]). Isolates with an echinocandin MIC of \>2 μg/mL are classified as non-susceptible.

A previous multi-center study has demonstrated that this methodology has high interlaboratory reproducibility ([@b79-idr-1-063]). Interestingly, some in vitro studies have reported enhanced potency of anidulafungin and micafungin against *Candida* species compared to caspofungin ([@b82-idr-1-063]; [@b20-idr-1-063]), while others have not noted differences in potency among the echinocandins ([@b89-idr-1-063]). The differences in in vitro potency observed by some investigators have not translated into improved efficacy in vivo. Two studies have reported similar efficacy among members of this class in murine models of invasive fungal infections, including candidiasis and aspergillosis, despite the greater in vitro potency of anidulafungin and micafungin ([@b83-idr-1-063]; [@b114-idr-1-063]). In these studies, the in vivo activity correlated better with the in vitro potency of these agents when tested in the presence of human serum. The effect of serum on the activity of the echinocandins is not fully understood. One potential explanation is that the observed reduction in potency is due to the significant protein binding associated with each of these agents ([@b2-idr-1-063]). Although this reduction in echinocandin potency may be secondary to the high degree of protein binding, a previous study with micafungin reported that the activity of this echinocandin remained greater than 50-fold higher than the free drug concentrations predicted by the protein binding ratio ([@b74-idr-1-063]). Thus, although micafungin may demonstrate enhanced in vitro potency compared to caspofungin against clinical isolates, this may not translate into enhanced clinical efficacy. Indeed, a clinical trial directly comparing micafungin to caspofungin for the treatment of candidemia and invasive candidiasis demonstrated similar clinical outcomes among the various treatment groups ([@b84-idr-1-063]).

Mechanisms of resistance
------------------------

As the clinical use of the echinocandins continues to grow, reports of echinocandin failure associated with elevated MIC values continue to appear in the literature. Currently, the most established mechanism for reduced echinocandin susceptibility is an alteration in the glucan synthase enzyme complex. Genetic studies in *Saccharomyces cerevisiae* and *C. albicans* first suggested that alterations within this essential component of glucan synthase cause a reduced affinity of the echinocandins to this enzyme and could account for elevated MICs to this class of agents ([@b27-idr-1-063]; [@b26-idr-1-063]). These studies identified several single nucleotide polymorphisms (SNPs) that may occur within *FKS1*, the gene encoding for Fks1p, a subunit of the glucan synthase enzyme complex that is inhibited by the echinocandins ([@b7-idr-1-063]). These SNPs occur within two regions of *FKS1*, and result in single amino acid substitutions within highly conserved regions of Fks1p. The first region associated with decreased echinocandin activity spans approximately 10 amino acids while the second region comprises 20 amino acids ([Figure 1](#f1-idr-1-063){ref-type="fig"}). Substitutions within these regions have been associated with increased echinocandin MICs in spontaneous laboratory *C. albicans* mutants and clinical isolates ([@b85-idr-1-063]). These amino acid changes also resulted in a significant increase in the echinocandin 50% inhibitory concentration (IC~50~) against glucan synthase activity ([@b26-idr-1-063]). In *C. albicans*, mutations within the highly conserved hot spot regions of *FKS1* have been reported to lead to codon changes F641S, S645F, S645Y, S645P, and R1361H ([@b85-idr-1-063]; [@b7-idr-1-063]). Similar changes have been reported in a number of clinical non-*C. albicans* isolates with reduced echinocandin susceptibility ([Table 2](#t2-idr-1-063){ref-type="table"}) collected from patients who experienced clinical failure while receiving an echinocandin ([@b47-idr-1-063]; [@b17-idr-1-063]; [@b31-idr-1-063]). In *C. glabrata*, SNPs in *FKS1* and *FKS2* result in amino acid changes that confer reduced susceptibility and have been documented in patients failing echinocandin therapy ([@b17-idr-1-063]; [@b104-idr-1-063]). Interestingly, a recent study has demonstrated that the reduced potency of echinocandins against *C. parapsilosis* and the closely related species *C. orthopsilosis* and *C. metopsilosis*is due to a naturally occurring proline-to-alanine substitution at amino acid 660 (P660A) at the end of one of the highly conserved hot spot regions within Fks1p ([@b30-idr-1-063]). Other mechanisms that may result in reduced echinocandin susceptibility include overexpression of the Golgi protein Sbe2p, which is involved in cell wall component transport ([@b80-idr-1-063]), up-regulation of the cell wall integrity pathway ([@b112-idr-1-063]), and increases in cell wall chitin content ([@b88-idr-1-063]; [@b101-idr-1-063]; [@b21-idr-1-063]). The clinical significance of these other mechanisms is unknown.

In many of the case reports detailing clinical failure associated with reductions in echinocandin susceptibility, reduced potency occurred over a prolonged period of echinocandin therapy or in patients with an untreated focus of infection (ie, central venous catheter, prosthesis) ([@b86-idr-1-063]; [@b37-idr-1-063]; [@b17-idr-1-063]). In one case report of a patient with esophageal candidiasis who failed micafungin, the MIC values rose significantly over 6-week period of therapy from a baseline value of 0.06 μg/mL with similar decreases in susceptibility also observed for anidulafungin and caspofungin ([@b60-idr-1-063]). In some reports, the MIC values for anidulafungin and micafungin remained below the recently established CLSI breakpoint for echinocandin susceptibility, despite a caspofungin MIC of \>2 μg/mL, but normalized when tested in the presence of serum ([@b114-idr-1-063]; [@b104-idr-1-063]). Similar results have been demonstrated in vivo and correlated to in vitro susceptibility testing done in the presence of serum ([@b114-idr-1-063]; [@b67-idr-1-063]), suggesting that switching to a different echinocandin when resistance is noted for another member of this class may not be appropriate ([@b89-idr-1-063]). Despite the publication of numerous case reports of echinocandin clinical failure associated with reduced in vitro susceptibility, clinical failure due to echinocandin resistance appears to be of limited clinical scope as surveillance studies have not revealed significant changes in the activity of these agents ([@b90-idr-1-063]; [@b89-idr-1-063]).

Pharmacodynamics
----------------

Micafungin demonstrates concentration-dependent activity against *Candida* and *Aspergillus* species in vitro and in preclinical animal models. Against *C. albicans*, *C. glabrata*, and *C. krusei*, micafungin demonstrated fungicidal activity in time-kill studies, defined as a ≥3 log~10~ reduction in colony-forming units per milliliter from the starting inoculum, with improved activity at higher concentrations ([@b28-idr-1-063]). However, against *C. tropicalis*, fungistatic activity was observed. In animal studies of invasive candidiasis, increases in survival and reductions in tissue fungal burden have been described at doses of ≥0.125 mg/kg ([@b46-idr-1-063]; [@b66-idr-1-063]; [@b87-idr-1-063]). Free drug area under the concentration curve to MIC ratios (AUC/MIC) of 10 and 20 have been associated with stasis and a 1 log~10~ reduction in tissue fungal burden (CFU per gram of kidney tissue), respectively, against susceptible *C. albicans* and *C. glabrata* isolates in a murine model of invasive candidiasis ([@b2-idr-1-063]). These values for stasis and a 1-log reduction in fungal burden were similar to the AUC/MIC ratios for anidulafungin reported by the same investigators ([@b1-idr-1-063]). Because of the long half-lives achieved clinically and the tolerability observed in dose escalation trials ([@b14-idr-1-063]; [@b43-idr-1-063]; [@b99-idr-1-063]), extended-interval dosing of the echinocandins has been suggested as a means of overcoming the need for daily intravenous therapy. This strategy has been demonstrated to be effective in a murine model of disseminated candidiasis in which a single large dose of micafungin (100 mg/kg) effectively reduced tissue fungal burden with no evidence of regrowth after 7 days in mice inoculated with *C. glabrata* ([@b35-idr-1-063]).

In animal models of invasive aspergillosis, increasing doses of micafungin have been shown to improve survival ([@b46-idr-1-063]; [@b87-idr-1-063]; [@b45-idr-1-063]). However, reductions in tissue fungal burden have not been consistently reported with increasing doses. In fact, a paradoxical attenuation of of echinocandin activity at higher concentrations despite an inhibitory effect at lower drug levels has been reported both in vitro and in vivo. In *Candida* species, the attenuated activity occurs within a range of 4 to 32 μg/mL ([@b94-idr-1-063]; [@b100-idr-1-063]; [@b112-idr-1-063]), and is both echinocandin and *Candida* species specific. In a study of 60 *Candida* bloodstream isolates, the highest frequency of this phenomenon was observed with caspofungin, occurring in 90% of *C. parapsilosis*, 60% of *C. albicans*, 40% of *C. tropicalis*, and in 1 *C. krusei* isolate ([@b15-idr-1-063]). For anidulafungin, this effect was reported in 40% of *C. albicans* and 20% of the *C. tropicalis* isolates tested. In contrast, a paradoxical effect was not observed for micafungin against any *C. albicans* or *C. parapsilosis* isolates, but did occur in *C. tropicalis* (70%) and *C. krusei* (60%) isolates. Paradoxical increases in markers of disease burden have been reported with higher doses of the ecinocandins in animal models of invasive aspergillosis. For micafungin, an increase in serum galactomannan antigenemia was reported at a dose of 2 mg/kg/day compared to 1 mg/kg/day reported in a neutropenic rabbit model of invasive pulmonary aspergillosis ([@b87-idr-1-063]). In addition, the mean total lung weight of animals that received dosages of 2 mg/kg/day of micafungin did not differ from that of infected controls even though a reduction was reported with a lower dosage. However, higher doses of micafungin did result in further damage to the hyphae and this was associated with significant reductions in pulmonary infarct scores. Similarly, in a murine model of central nervous system aspergillosis, micafungin dosages of 10 mg/kg/day did not result in significant clearance of residual fungal burden as measured by colony-forming units from the secondary site of infection, the kidneys, despite a significant reduction in animals treated with 5 mg/kg/day ([@b18-idr-1-063]). In contrast, a recent study comparing micafungin to caspofungin in a murine model of invasive pulmonary aspergillosis reported no increases in pulmonary fungal burden as measured by quantitative real-time PCR with higher doses of micafungin compared to a modest paradoxical effect observed with caspofungin ([@b62-idr-1-063]). Although the paradoxical effect has been inconsistently reported in animal studies, it is important to remember that this effect appears to be echinocandin-dependent for the specific species in question for both *Candida* and *Aspergillus* species ([@b15-idr-1-063]; [@b3-idr-1-063]). Where this phenomenon may impact therapy is with extended interval dosing of the echinocandins as therapy or prophylaxis against invasive aspergillosis. Indeed, one study reported worse survival, increased pulmonary fungal burden, and persistent hyphal clusters within the lungs as measured by histopathology in mice that received a single dose of micafungin 20 mg/kg as prophylaxis compared to a lower dose of 10 mg/kg ([@b63-idr-1-063]).

Recently, attention has focused on the immunomodulatory effects of the echinocandins against fungi secondary to the effects of these agents on (1→3)-β-D-glucan. Besides having an important role on fungal cell wall structure, (1→3)-β-D-glucan exhibits immunostimulatory properties secondary to recognition by the innate immune receptor Dectin-1 on alveolar macrophages, neutrophils, and dendritic cells ([@b13-idr-1-063]; [@b103-idr-1-063]). This binding of (1→3)-β-D-glucan by Dectin-1 triggers phagocytosis, the release of pro-inflammatory cytokines, and the generation of reactive oxygen intermediates ([@b13-idr-1-063]). Recent studies have demonstrated that echinocandin-induced morphological changes in hyphae of filamentous fungi result in increased cell wall exposure of (1→3)-β-D-glucan and Dectin-1 mediated pro-inflammatory responses by macrophages and neutrophils ([@b44-idr-1-063]; [@b59-idr-1-063]). It is noteworthy that this pro-inflammatory response has been primarily studied upon exposure of hyphae to caspofungin. However, enhanced polymorphonuclear neutrophil-mediated damage has also been observed when *A. fumigatus* hyphae are preincubated with anidulafungin and micafungin ([@b59-idr-1-063]). Previous studies have demonstrated *A. fumigatus* hyphae that have not been exposed to an echinocandin illicit a Th2 mediated inflammatory response in dendritic cells resulting in poor outcomes in an animal model of invasive aspergillosis ([@b11-idr-1-063]; [@b12-idr-1-063]). Further work in experimental models of invasive fungal infections using a wide range of echinocandin doses are needed to fully determine the clinical relevance of the immunomodulatory effects of these agents.

Pharmacokinetics
================

Micafungin has linear pharmacokinetics over a wide range of doses ([@b39-idr-1-063]; [@b43-idr-1-063]). In healthy adult volunteers the mean peak plasma concentration (Cmax) and area under the concentration curve (AUC) were 8.8 μg/mL and 125.9 μg × h/mL, respectively, following a single 100 mg dose ([@b39-idr-1-063]). In a randomized, double-blind dose escalation study similar pharmacokinetic values were observed for micafungin doses ranging from 12.5 to 200 mg/day in adult patients undergoing bone marrow or peripheral stem cell transplantation ([@b43-idr-1-063]). In this study, micafungin exposure was proportional to the dose administered with accumulation of the drug from days 1 to 7 following linear pharmacokinetics. In adults, the volume of distribution of micafungin approximates that of the extracellular fluid (0.26 to 0.39 L/kg) ([@b39-idr-1-063]; [@b41-idr-1-063]). Similar to anidulafungin and caspofungin, micafungin is extensively protein-bound in the plasma (\>99.5%) ([@b76-idr-1-063]). The effects of protein binding on the activity of echinocandins are not fully understood as studies on the effects of protein binding on echinocandin activity have reported conflicting results. While one early study demonstrated enhanced activity of caspofungin against *A. fumigatus* in the presence of sera ([@b16-idr-1-063]), other studies have reported reduced potency of members of this class in the presence of human sera. Mochizuki et al reported that the MIC of micafungin against *C. albicans* increased 8-fold in the presence of inactivated sera ([@b74-idr-1-063]). However, the activity of micafungin was 50-fold higher than that predicted by the free drug concentration profile. Another recent study comparing each of the three available echinocandins reported a reduction in the activity of each agent with the addition of 50% human sera, resulting in the neutralization of the enhanced potency of micafungin relative to caspofungin both in vitro and in vivo ([@b83-idr-1-063]).

The pharmacokinetics of micafungin have also been evaluated in pediatric patients. Micafungin was administered at doses ranging from 0.5 to 4 mg/kg/day in an open-label phase I study of patients with febrile neutropenia ranging from age 2 to 17 years ([@b98-idr-1-063]). Similar to adults, C~max~ and AUC values increased in a linear fashion. However, consistent with previous studies of antifungal agents that have demonstrated greater clearance and reduced exposure in pediatric patients compared to adolescents and adults, a higher clearance and volume of distribution and shorter half-life were observed in patients age 2 to 8 years compared to those 9 to 17 years old ([Table 3](#t3-idr-1-063){ref-type="table"}) ([@b61-idr-1-063]; [@b110-idr-1-063]; [@b109-idr-1-063]). In neonates less than or equal to 40 weeks gestational age and weighing at least 1000 g, linear increases in C~max~ and AUC values were also observed following single doses of 0.75, 1.5, and 3 mg/kg ([@b41-idr-1-063]). Micafungin clearance was also increased in this group (1.7-fold higher than that of children age 2--8 years, and 2.6-fold higher than adolescents age 9--17 years).

Micafungin undergoes limited phase I metabolism to three metabolites (M1, M2, and M5). The M1 metabolite is formed by metabolism of the parent drug by arylsulfatase, and this metabolite is further degraded by cathechol-O-methyltransferase to M2. The third metabolite, M5, is formed by hydroxylation of the side chain by CYP450 isoenzymes. However, the cumulative AUC and C~max~ of these three metabolites have been reported to be approximately 8% and 4%, respectively, of the parent compound in healthy volunteers at steady state ([@b50-idr-1-063]). The primary route of micafungin elimination is through fecal excretion ([@b76-idr-1-063]). In a health volunteer study ^14^C-radiolabeled micafungin was administered as a 25 mg dose to healthy volunteers. In this study, 71% of micafungin clearance occurred via biliary elimination via the fecal route as either unchanged parent drug or metabolite.

Because micafungin is not cleared renally and undergoes limited hepatic metabolism, its pharmacokinetic parameters appear to be unchanged in patients with hepatic or renal dysfunction. In a phase I, open-label, 100 mg single-dose pharmacokinetic study no differences in peak plasma concentration, clearance, volume of distribution, or half-life were observed among patients with: 1) moderate hepatic impairment (Child-Pugh score 7--9), 2) creatinine clearance \<30 mL/min, and 3) age and gender matched healthy controls ([@b39-idr-1-063]). No differences in AUC were noted between patients with renal dysfunction and healthy controls. Patients with moderate hepatic impairment did have a lower micafungin AUC (97.5 μg × h/mL) compared to healthy controls (125.9 μg × h/mL), although this may have been due to a significantly higher mean body weight in this group compared to healthy controls. Hypoalbuminemia resulting in alterations in protein binding may also be a potential explanation for the reduced micafungin AUC in patients with hepatic impairment due to the high protein binding of this drug. Reductions in albumin may increase the volume of distribution as more drug is able to distribute out of the bloodstream, which has been shown to occur for micafungin in animals with acute hepatic failure ([@b52-idr-1-063]). However, no changes in the weight-adjusted volume of distribution were observed between healthy subjects and those with moderate hepatic impairment in the study by [@b39-idr-1-063]. A subsequent study also reported no influence of hypoalbuminemia on micafungin plasma concentrations ([@b77-idr-1-063]). Currently, no dosage adjustments are recommended for patients with mild to moderate hepatic or mild, moderate, or severe renal impairment ([@b76-idr-1-063]).

Interestingly, a recent study has demonstrated that patient weight influences the clearance of micafungin. Using a population pharmacokinetic analysis with serum micafungin concentration data from a previous study of bone marrow transplant recipients, Gumbo et al identified patient weight to be a significant covariate on the serum clearance of this echinocandin ([@b36-idr-1-063]). The clearance of micafungin in patients weighing 66.3 kg or greater was increased by 50% compared to those weighing less than this amount. Because increased clearance impacts the overall drug exposure, as measured by the AUC, and the pharmacokinetic/pharmacodynamic parameter associated with the in vivo activity of micafungin is the AUC/MIC ratio ([@b35-idr-1-063]; [@b2-idr-1-063]), the authors speculated that this may negatively affect heavier patients infected with *Candida* isolates with higher MIC values if the dose is not increased. However, it is unknown if this finding indeed has clinical implications.

Adverse effects
===============

Micafungin is well tolerated with few drug-related adverse effects reported in clinical trials. No differences in safety profiles were observed between micafungin and fluconazole, a relatively well-tolerated antifungal, in head-to-head trials of these two agents ([@b106-idr-1-063]; [@b22-idr-1-063]; [@b23-idr-1-063]). Rash, chills, nausea, vomiting, diarrhea, headache, and injection site reactions have been the most commonly reported adverse events ([@b22-idr-1-063]; [@b23-idr-1-063]; [@b81-idr-1-063]; [@b24-idr-1-063]). Pruritus, facial swelling, and vasodilation have also been reported and may be due to histamine release that occurs with the intravenous administration ([@b76-idr-1-063]). Adverse laboratory effects associated with micafungin are generally mild and include elevated transaminases, alkaline phosphatase, and serum bilirubin ([@b106-idr-1-063]; [@b23-idr-1-063]; [@b76-idr-1-063]). Overall, few patients enrolled in clinical trials have discontinued micafungin due to adverse effects related to this drug.

The excellent safety profile, favorable pharmacokinetics, and concentration-dependent activity of micafungin have led several investigators to evaluate the safety of dosage escalation with this agent. In adult bone-marrow or peripheral stem cell transplant patients randomized to either micafungin or placebo for up to 4 weeks, grade 3 or higher toxicities thought to be related to this echinocandin were observed in 4 patients at dosages of 150 or 200 mg/day ([@b43-idr-1-063]). These included atrial fibrillation, hypokalemia, pancreatitis, and maculopapuler rash. However, since the same grade 3 or higher toxicity was not observed in at least 3 patients in the same dosage group, the criterion for the maximum-tolerated dose was not met. A maximum-tolerated dose of micafungin was also not observed in an open-label study of hematopoietic stem cell transplant recipients who received dosages of 3, 4, 6, or 8 mg/kg/day for a period of 8 days to 4 weeks ([@b99-idr-1-063]). No patients developed grade 3 or 4 toxicities related to micafungin, and one patient was able to tolerate a dose of 900 mg/day. In addition, no significant changes in transaminase levels were reported, and the adverse effects observed were mild to moderate in severity. Similarly, a maximum tolerated dose was not observed in neutropenic patients age 2 to 17 years, including autologous and allogeneic hematopoietic stem cell transplant recipients, who received micafungin at 0.5 to 4 mg/kg/day up to a maximum of 200 mg/day ([@b98-idr-1-063]).

Drug interactions
=================

One of the advantages of micafungin over the azole antifungals is that few clinically significant drug interactions are associated with this echinocandin. Although micafungin appears to be a mild inhibitor of cytochrome P450 3A4 in vitro, this appears to be of minimal clinical significance as no interactions have been found with the known 3A4 inhibitors fluconazole, voriconazole, and ritonavir or with the potent inducer rifampin ([@b43-idr-1-063]; [@b50-idr-1-063]; [@b76-idr-1-063]). Healthy volunteer studies have demonstrated increases in nifedipine AUC (18%) and C~max~ (42%) values in the presence of steady-state micafungin concentrations ([@b97-idr-1-063]; [@b76-idr-1-063]). Similarly, micafungin has been shown to increase the AUC of sirolimus by 21%. In addition, the AUC and C~max~ of itraconazole may be increased with co-administration of micafungin ([@b76-idr-1-063]). Thus, it is recommended that patients receiving sirolimus, nifedipine, or itraconazole in combination with micafungin be monitored for signs and symptoms of toxicity, and that dosage reductions of these medications may be necessary ([@b76-idr-1-063]).

In healthy volunteers, micafungin AUC values have been reported to increase between 10% and 14% with concurrent administration of a single dose of cyclosporine ([@b40-idr-1-063]). Conversely, micafungin appears to be a mild inhibitor of cyclosporine metabolism, resulting in a decrease in the oral clearance and an increase in the half-life ([@b40-idr-1-063]). Although the clinical relevance of this interaction is unknown, careful monitoring of cyclosporine concentrations may be warranted as one-fifth of the volunteers in this study had potentially clinically significant increases in cyclosporine concentrations when coadministered with micafungin. Interestingly, no changes in tacrolimus or micafungin pharmacokinetic parameters were observed in a similar drug interaction study ([@b38-idr-1-063]).

Clinical efficacy
=================

Esophageal candidiasis
----------------------

The echinocandins have a useful role in the treatment of esophageal candidiasis, including azole-refractory infections, secondary to their excellent safety profile and limited number of clinically significant drug interactions. Micafungin has been shown in clinical studies to be as effective as fluconazole for the treatment of esophageal candidiasis. In a double-blind dose-ranging study of HIV-positive patients comparing different doses of micafungin to fluconazole (200 mg/day), a clear dose-response was noted in patients randomized to micafungin 50 mg (69%), 100 mg (77%), or 150 mg (90%) as measured by endoscopy ([@b22-idr-1-063]). Interestingly, despite similar endoscopic cure rates and clinical responses at the end of therapy, mycological eradication occurred in a higher percentage of patients who received micafungin 100 mg compared to those randomized to 150 mg (78% vs 57%, respectively; p = 0.031). However, successful treatment, defined as no evidence of esophageal candidiasis associated plaques at the end of therapy, did not differ significantly among patients randomized to receive micafungin 100 mg or 150 mg compared to fluconazole (87%). Similar outcomes were reported in a second trial comparing micafungin (150 mg/day) to fluconazole (200 mg/day) for the treatment of endoscopy confirmed esophageal candidiasis ([@b23-idr-1-063]). In this study, endoscopic cure at the end of therapy was similar between patients randomized to micafungin and fluconazole (88% in both treatment groups). In each study, micafungin was reported to be well tolerated with rash, fever, and phlebitis the most commonly observed adverse effects.

Relapses following discontinuation of therapy have been reported in clinical trails for each member of the echinocandin class, raising concerns about the use of these agents for the treatment of esophageal candidiasis. In the first study discussed above, relapses were reported in 9 patients randomized to micafungin and in none who received fluconazole ([@b22-idr-1-063]). Similarly, in the second study approximately 15% of patients who received micafungin relapsed following discontinuation of therapy ([@b23-idr-1-063]). However, 11% of patients randomized to fluconazole also relapsed after the end of treatment. Similar relapse rates have also been reported for caspofungin and fluconazole during the post-treatment period (11% and 8%, respectively) ([@b107-idr-1-063]) as well as for anidulafungin (35%) ([@b55-idr-1-063]). Thus, it is unknown if the relapses following discontinuation of treatment for esophageal candidiasis is a property specific for the echinocandins.

Candidemia/invasive candidiasis
-------------------------------

A primary use of the echinocandins is for the treatment of invasive candidiasis. Micafungin has been evaluated for the treatment of patients with invasive candidiasis/candidemia in three clinical trials. In an open-label, noncomparative study, micafungin, either alone or in combination with another antifungal agent, was shown to be effective in patients with newly diagnosed or refractory candidemia ([@b81-idr-1-063]). The initial dose of micafungin was 50 mg/day (1 mg/kg for patients less than 40 kg) for the treatment of *C. albicans* infections, and 100 mg per day for infections caused by other *Candida* species. Overall treatment success, defined as a complete or partial response based on the global assessment of clinical and mycological response at the end of therapy, was 76% in patients who received at least one dose of micafungin, and increased to 83% in patients who received at least five doses. Response rates were similar among patients who received micafungin in combination for refractory disease (79%), alone for newly diagnosed candidemia (87%), or alone for refractory candidemia (76%). As this trial was a preliminary study to obtain data on the efficacy of micafungin for the treatment of candidemia, the dose used for the treatment of infections caused by *C. albicans* (50 mg/day) was lower than in subsequent studies, where the minimum dose was 100 mg/day regardless of the infection.

The efficacy of micafungin for invasive candidiasis/candidemia has also been compared to that of liposomal amphotericin B. In a double-blind, non-inferiority study patients were randomized to receive either micafungin 100 mg/day or liposomal amphotericin B administered as 3 mg/kg/day ([@b58-idr-1-063]). The majority of patients enrolled in this study had candidemia, and the causative agent of infection was frequently a non-*albicans* species: 62% in micafungin patients and 59% in those randomized to liposomal amphotericin B. In the intent-to-treat analysis overall treatment success, defined as clinical and mycological response at the end of therapy, was observed in 72% of patients in the micafungin group and 68% of those who received liposomal amphotericin B. No differences were observed among patients infected with different *Candida* species. Similar to a previous study that compared caspofungin to amphotericin B deoxycholate ([@b75-idr-1-063]), micafungin was better tolerated with a lower incidence of nephrotoxicity and infusion-related reactions than those observed with liposomal amphotericin B.

Results from a pediatric sub-study as part of the micafungin versus liposomal amphotericin B study have recently been published ([@b93-idr-1-063]). In this study, micafungin was administered at a dose of 2 mg/kg/day and liposomal amphotericin B at 3 mg/kg/day. This dose of micafungin was used secondary to the shorter half-life and faster clearance observed in premature infants and young children ([@b98-idr-1-063]; [@b41-idr-1-063]). Overall treatment success was similar between patients who received micafungin (73%) and those that received liposomal amphotericin B (76%). The treatment success rates were consistent across age groups and in patients who were born prematurely, and mycologic persistence at the end of therapy was observed in 16% of patients in both treatment groups. Similar to the adult study, discontinuation of therapy due to adverse effects was lower in the micafungin group compared to liposomal amphotericin B (3.8% vs 17%, respectively).

In the two previously described studies, as well as other studies that have evaluated caspofungin and anidulafungin for the treatment of invasive fungal infections, a member of another antifungal class has been used as the active comparator. To date, only one clinical trial has directly compared two echinocandins for the treatment of invasive fungal infections. In this double-blind, non-inferiority study, patients were randomized to receive either micafungin 100 mg/day or 150 mg/day, or caspofungin, administered at 70 mg on the first day and 50 mg/day thereafter, for the treatment of invasive candidiasis/candidemia ([@b84-idr-1-063]). Overall success, again defined as a favorable clinical and mycological response at the end of therapy, was similar among the three groups with 74% of patients randomized to micafungin 100 mg, 70% to micafungin 150 mg, and 71% in those who received caspofungin having a favorable outcome. Interestingly, a higher response rate was reported for the higher dose of micafungin in patients with infections caused by *C. glabrata*. However, this study was not sufficiently powered to assess differences among *Candida* species. These results demonstrate that micafungin is as effective as caspofungin for the treatment of invasive candidiasis/candidemia. Similar safety profiles among the treatment groups were also reported. Although a clear dose-response was observed in an early study that compared micafungin to fluconazole for the treatment of esophageal candidiasis, such an effect was not observed in this study as micafungin 100 mg/day was as effective as the higher dose of 150 mg/day. Overall, the response rates reported in the studies that have evaluated micafungin for invasive candidiasis/candidemia are similar to those observed for caspofungin and anidulafungin as well as other antifungal agents in clinical studies ([Figure 2](#f2-idr-1-063){ref-type="fig"}) ([@b96-idr-1-063]; [@b75-idr-1-063]; [@b56-idr-1-063]; [@b95-idr-1-063]).

Antifungal prophylaxis
----------------------

Antifungal prophylaxis has been shown to reduce the incidence of invasive fungal infections and in some studies to improve survival ([@b33-idr-1-063]; [@b115-idr-1-063]; [@b71-idr-1-063]; [@b19-idr-1-063]; [@b105-idr-1-063]). However, this strategy is often limited by the drug interactions and adverse effects associated with the azoles and amphotericin B formulations. The echinocandins offer an alternative strategy as antifungal prophylaxis secondary to their favorable adverse effect profile and lack of clinically relevant drug interactions. In a prospective, double-blind, multicenter study that included autologous and allogeneic stem cell transplant recipients, patients were randomized to receive either micafungin 50 mg/day (1 mg/kg for those weighing less than 50 kg) or fluconazole 400 mg/day (8 mg/kg in those weighing less than 50 kg) ([@b106-idr-1-063]). Prophylaxis was initiated in the pre-engraftment period and continued until approximately 5 days after engraftment or up to 42 days post-transplant. Treatment success was defined as the absence of proven, probable, or suspected systemic fungal infections at the end of prophylaxis and the absence of proven or probable systemic fungal infections at the end of the 4-week follow-up period. Patients randomized to micafungin experienced higher treatment success compared to those who received fluconazole (80% vs 74%; p = 0.03). No difference in breakthrough candidiasis was observed between the two groups. Instead, this difference was primarily due to fewer cases of breakthrough invasive aspergillosis in the micafungin group (1 patient) compared to fluconazole (7 patients). Less empiric antifungal therapy was also required in the micafungin group compared to fluconazole (15% vs 21%, respectively; p = 0.024). One of the limitations of this study is that the median duration of prophylaxis was only 18 days. Thus, it is unclear how effective micafungin prophylaxis would be in the setting of graft-versus host disease and corticosteroid therapy in allogeneic stem cell transplant recipients, as observational studies have demonstrated an increased risk of invasive aspergillosis during the post-engraftment period ([@b108-idr-1-063]).

Invasive aspergillosis
----------------------

Micafungin does not currently have an indication for the treatment of invasive aspergillosis and data on its use against this opportunistic infection are limited. In one open-label, non-comparative study, micafungin was evaluated as primary therapy or as salvage therapy in patients who had failed previous therapy or were intolerant of other antifungal agents ([@b24-idr-1-063]). Patients were initially dosed at 75 mg/day with dosage escalation permitted if disease progression occurred or if cultures remained positive. A favorable response, defined as either a complete or partial response at the end of therapy based on radiological, mycological, and clinical data, was observed in 36% of patients who received at least one dose of micafungin. However, disease progression was observed in 53% of patients during the course of treatment. Patients in whom neutrophil recovery occurred had a favorable response rate of 50% compared to only 17% in those who remained neutropenic. During the 6-week follow-up period, overall mortality was 56%, of which 59% was considered to be attributable to invasive aspergillosis. Overall, the results of micafungin monotherapy in this study (41% favorable response rate) are similar to those reported for caspofungin monotherapy in patients receiving this echinocandin as salvage therapy for invasive aspergillosis (45%) ([@b65-idr-1-063]). In patients with refractory disease who received micafungin in combination with other antifungal therapy, response rates were less favorable (35% with a favorable response; 60 of 174). Responses were especially poor in allogeneic stem cell transplant recipients who were receiving salvage antifungal combination therapy (25% with a favorable response; 21 of 83) ([@b54-idr-1-063]). Similarly low response rates have been reported for caspofungin in combination with other antifungal therapy for the salvage treatment of invasive aspergillosis ([@b53-idr-1-063]), highlighting the difficulty in treating patients with refractory disease.

Conclusion
==========

The echinocandins have been a welcome addition to the antifungal armamentarium. Major advantages of this class of agents include the potent activity against *Candida* and *Aspergillus* species, as well as the excellent safety compared to amphotericn B formulations and fewer drug interactions than the azoles. Clinical studies have demonstrated micafungin to be as safe and as effective as fluconazole for the treatment of esophageal candidiasis. In addition, micafungin is as effective as liposomal amphotericin B and caspofungin for the treatment of invasive candidiasis/candidemia. Notably, fewer adverse effects were observed for micafungin compared to liposomal amphotericin B in both adults and pediatric patients. The utility of micafungin against invasive aspergillosis is less clear. Although potent in vitro activity is observed against *Aspergillus* species, and these results are supported by preclinical in vivo studies, clinical data supporting the use of micafungin against invasive aspergillosis are scarce. Thus, while micafungin appears to be a suitable option for the treatment of invasive candidiasis/candidemia, further studies are needed to accurately judge its role in the treatment of invasive aspergillosis.
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###### 

Microdilution minimum inhibitory concentration and minimum effective concentration (μg/mL) for the clinically available echinocandins against *Candida* and *Aspergillus* species ([@b102-idr-1-063]; [@b5-idr-1-063]; [@b29-idr-1-063]; [@b42-idr-1-063]; [@b81-idr-1-063]; [@b90-idr-1-063]; [@b73-idr-1-063]; [@b90-idr-1-063]; [@b91-idr-1-063]; [@b30-idr-1-063])

  **Species**                 **Micafungin**   **Anidulafungin**   **Caspofungin**                                      
  --------------------------- ---------------- ------------------- ----------------- ------------------ --------------- -------------------
  ***Candida* species**                                                                                                 
  *C. albicans*               0.01 to ≥8       0.01--0.5           0.01 to ≥8        0.01--0.5          0.01 to ≥8      0.12--1
  *C. glabrata*               0.01 to ≥8       0.01--0.5           0.01--8           0.12--0.5          0.01 to ≥8      0.06--1
  *C. parapsilosis*           0.03 to ≥8       1 to \>8            0.01 to ≥8        2 to \>8           0.03 to ≥8      1--4
  *C. tropicalis*             0.01 to ≥8       0.03--2             0.03 to ≥8        0.06--2            0.03 to ≥8      0.06--1
  *C. krusei*                 0.06--4          0.12--0.25          0.01--8           0.03--1            0.12 to ≥4      0.25-- 2
  **Species**                 **MEC range**    **MEC~90~ range**   **MEC range**     **MEC~90~range**   **MEC range**   **MEC~90~ range**
                                                                                                                        
  ***Aspergillus* species**                                                                                             
  *A. fumigatus*              0.007--0.125     0.015--0.125        0.06              0.06               0.06--0.125     0.125
  *A. terreus*                0.004--0.008     0.004--0.008        0.03              0.03               0.125--2        1
  *A. flavus*                 0.003--0.125     0.015--0.125        0.03--0.125       0.03--0.125        0.03--0.125     0.125
  *A. niger*                  0.007--0.0125    0.008--.125         0.03--0.125       0.06--0.125        0.125--2        0.125--1

**Abbreviations:** MEC, minimum effective concentration; MIC, minimum inhibitory concentration.

###### 

Amino acid sequences and nucleotide changes in susceptible and resistant isolates from various *Candida* species reported in the literature

  **Isolates**                                                   **Protein sequence**            **Nucleotide change**   **Caspofungin MIC (μg/mL)**
  -------------------------------------------------------------- ------------------------------- ----------------------- -----------------------------
  ***Candida albicans* (Wiederhold et al 2008)**                                                                         
  SC5314                                                         FLTLSLRDP                       --                      0.125
  2762                                                           ***S***LTLSLRDP                 T1922C                  4
  53264                                                          FLTL***P***LRDP                 T1933C                  4
  ***Candida glabrata* ([@b104-idr-1-063]; [@b17-idr-1-063])**                                                           
  7754                                                           FFLILSLRDP                      --                      0.25
  7755                                                           F***V***LILSLRDP (Hot Spot 1)   T1975G                  2
  06-3169                                                        FLILSLR***E***P (Hot Spot 2)    T1896G                  \>2
  ***Candida krusei* ([@b47-idr-1-063])**                                                                                
  Ck-98                                                          FLILSIRDP                       --                      0.25
  Ck-100                                                         ***C***LILSIRDP                 T2080K                  8
  **Candida tropicalis ([@b31-idr-1-063])**                                                                              
  ATCC 750                                                       FLTSLRDP                        --                      0.25
  T3                                                             FLTLS/***P***LRDP               T1935C                  4
  T26                                                            ***L***LTLSLRDP                 T1923C                  1
  ***Candida parapsilosis* (Codon Change) ([@b30-idr-1-063])**                                                           
  ATCC 22019                                                     FLTLSLRD***A***                 P660A                   1.4
  H4                                                             FLTSLRD***A***                  P660A                   2.24

**Note:** Bolded and italicized letters refer to amino acid changes within protein sequences as a result of a nucleic acid point mutation.

**Abbreviation:** MIC, minimum inhibitory concentration.

###### 

Mean micafungin pharmacokinetic parameters (±SD) by different age groups and different doses in pediatric and adult patients ([@b39-idr-1-063]; [@b43-idr-1-063]; [@b98-idr-1-063]; [@b41-idr-1-063])

  **Age group**                     **Clearance (mL/h/kg)**   **Half-life (h)**         **Volume distribution (L/kg)**
  --------------------------------- ------------------------- ------------------------- --------------------------------
  Neonates \>1000 g                 38.9 (12.1)               8.3 (1.8)                 0.435 (0.11)
  Children 2--8 yrs                 22.5 (8.6)                11.5 (2.9)                0.335 (0.16)
  Adolescents 9--17 yrs             15.1 (6.3)                13.4 (3.8)                0.243 (0.07)
  Adults                            14.6 (3.4)                13.1 (3.0)                0.256 (0.01)
  **Adult PK parameters by dose**   **C~max~ (μg/mL)**        **AUC (μg** × **h/mL)**   
  50 mg                             5.1 (1.0)                 54 (13)                   
  100 mg                            10.1 (2.6)                115 (25)                  
  150 mg                            16.4 (16.4)               167 (167)                 

**Abbreviations:** PK, pharmacokinetic.
